CGD's new clinical trials report was featured in a PharmaTimes article.
From the Article
Regional pathways for the regulation and ethical review of clinical trials, coupled with new processes for the design and conduct of faster, cheaper and more effective studies, are imperative if the growing pipeline of drugs and vaccines for neglected diseases is to deliver viable products to patients in need, a new report insists.
According to the report from the US-based Center for Global Development (CGD), the last decade has seen “tremendous” progress in developing products for the prevention, diagnosis and treatment of neglected diseases, bolstered by product development partnerships and research funding from the public and private sector.
There are now nearly 90 new products in the pipeline for conditions such as malaria and tuberculosis, with many of them approaching clinical trials, the CGD says.
Yet funding for global health is contracting while clinical trial costs can run to US$30,000 per patient, it warns. It can take “billions of dollars” to develop a new medicine and bring it to market in impoverished countries, finds the report on Safer, Faster, Cheaper: Improving Clinical Trials and Regulatory Pathways to Fight Neglected Diseases.